1. Home
  2. LBRDP vs TGTX Comparison

LBRDP vs TGTX Comparison

Compare LBRDP & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Broadband Corporation Series A Cumulative Redeemable Preferred Stock

LBRDP

Liberty Broadband Corporation Series A Cumulative Redeemable Preferred Stock

N/A

Current Price

$24.11

Market Cap

0.0

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$29.10

Market Cap

4.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LBRDP
TGTX
Founded
N/A
1993
Country
United States
United States
Employees
1900
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
4.9B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
LBRDP
TGTX
Price
$24.11
$29.10
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$50.67
AVG Volume (30 Days)
6.5K
1.4M
Earning Date
N/A
05-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1746.67
EPS
N/A
2.77
Revenue
N/A
$2,785,000.00
Revenue This Year
N/A
$48.75
Revenue Next Year
N/A
$25.01
P/E Ratio
N/A
$10.56
Revenue Growth
N/A
N/A
52 Week Low
$23.39
$25.37
52 Week High
$25.55
$46.48

Technical Indicators

Market Signals
Indicator
LBRDP
TGTX
Relative Strength Index (RSI) 53.26 45.92
Support Level $23.83 $27.51
Resistance Level $24.72 $30.00
Average True Range (ATR) 0.15 1.17
MACD 0.02 -0.04
Stochastic Oscillator 76.85 30.04

Price Performance

Historical Comparison
LBRDP
TGTX

About LBRDP Liberty Broadband Corporation Series A Cumulative Redeemable Preferred Stock

Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services, including video, internet, voice, and mobile services; commercial services, including small and medium business and enterprise solutions; advertising services; and other services. The company's reportable segments are GCI Holdings and Charter. The firm derives the majority of its revenue from GCI Holdings.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: